Crizanlizumab (SEG101)

Phase 3

Novartis AG (NVS)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Sickle Cell Disease (SCD)

View Full Landscape

Drug Information

Target Indication

Sickle Cell Disease (SCD)

Clinical Trial

NCT03814746

Last updated: 1/10/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA10/28/2020

Adakveo

Adakveo is indicated for the prevention of recurrent vaso occlusive crises (VOCs) in sickle cell disease patients aged 16 years and older. It can be given as an add on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate.

Conditional

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

NVS

Novartis AG

Pharmaceutical Preparations•Europe•NYSE

Related Pipeline

Peg-alpha interferon (Peg-Intron)Phase 3

Leukemia, Myeloid, Chronic

cyclosporin + mycophenolate mofetilPhase 3